Laser Direct-Write onto Live Tissues: A Novel Model for Studying Cancer Cell Migration.

Burks HE, Phamduy TB, Azimi MS, Saksena J, Burow ME, Collins-Burow BM, Chrisey DB, Murfee WL.

J Cell Physiol. 2016 Feb 29. doi: 10.1002/jcp.25363. [Epub ahead of print]

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.

Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, Boué SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010010. doi: 10.3390/ijerph13010010.

A novel gastrointestinal microbiome modulator from soy pods reduces absorption of dietary fat in mice.

Boué S, Fortgang I, Levy RJ Jr, Bhatnagar D, Burow M, Fahey G, Heiman ML.

Obesity (Silver Spring). 2016 Jan;24(1):87-95. doi: 10.1002/oby.21197. Epub 2015 Nov 20.

Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1.

Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM.

Oncogenesis. 2015 Oct 5;4:e168. doi: 10.1038/oncsis.2015.27.

Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.

Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, Gimble JM, Burow ME, Bunnell BA.

Breast Cancer Res. 2015 Aug 19;17:112. doi: 10.1186/s13058-015-0622-z.

Printing cancer cells into intact microvascular networks: a model for investigating cancer cell dynamics during angiogenesis.

Phamduy TB, Sweat RS, Azimi MS, Burow ME, Murfee WL, Chrisey DB.

Integr Biol (Camb). 2015 Sep;7(9):1068-78. doi: 10.1039/c5ib00151j. Epub 2015 Jul 20.

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM.

Oncotarget. 2015 Jun 30;6(18):16638-52.

Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.

Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE, Boue SM, Burow ME.

J Steroid Biochem Mol Biol. 2015 Jun;150:17-23. doi: 10.1016/j.jsbmb.2014.12.014. Epub 2015 Mar 12.

miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling.

Martin EC, Krebs AE, Burks HE, Elliott S, Baddoo M, Collins-Burow BM, Flemington EK, Burow ME.

Genes Cancer. 2014 Sep;5(9-10):353-64.

Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.

Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B.

Mol Carcinog. 2015 Dec;54(12):1656-67. doi: 10.1002/mc.22237. Epub 2014 Oct 18.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms.

Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA.

Stem Cell Res Ther. 2014 Aug 28;5(4):105. doi: 10.1186/scrt493.

Bisphenol A enhances adipogenic differentiation of human adipose stromal/stem cells.

Ohlstein JF, Strong AL, McLachlan JA, Gimble JM, Burow ME, Bunnell BA.

J Mol Endocrinol. 2014 Dec;53(3):345-53. doi: 10.1530/JME-14-0052. Epub 2014 Aug 20.

Effects of the endocrine-disrupting chemical DDT on self-renewal and differentiation of human mesenchymal stem cells.

Strong AL, Shi Z, Strong MJ, Miller DF, Rusch DB, Buechlein AM, Flemington EK, McLachlan JA, Nephew KP, Burow ME, Bunnell BA.

Environ Health Perspect. 2015 Jan;123(1):42-8. doi: 10.1289/ehp.1408188. Epub 2014 Jul 11.

Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.

Gestaut MM, Antoon JW, Burow ME, Beckman BS.

Pharmacol Rep. 2014 Feb;66(1):174-8. doi: 10.1016/j.pharep.2013.08.014. Epub 2014 Feb 3.

Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.

Strong AL, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Burow ME, Bunnell BA, Wang G.

ACS Med Chem Lett. 2013 Dec 10;5(2):143-8. doi: 10.1021/ml400397k. eCollection 2014 Feb 13.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9.

MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.

Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.

Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, Taylor CM, Flemington EK.

PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9.

Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition.

Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP, Burow ME.

Int J Oncol. 2013 Apr;42(4):1139-50. doi: 10.3892/ijo.2013.1814. Epub 2013 Feb 8.

Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line.

Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME.

PLoS One. 2012;7(11):e49067. doi: 10.1371/journal.pone.0049067. Epub 2012 Nov 30.

Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.

Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME.

Mol Carcinog. 2014 Jan;53(1):38-48. doi: 10.1002/mc.21946. Epub 2012 Aug 21.

Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Antoon JW, White MD, Driver JL, Burow ME, Beckman BS.

Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME.

Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.

Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.

Antoon JW, Bratton MR, Guillot LM, Wadsworth S, Salvo VA, Burow ME.

Cancer Biol Ther. 2012 Sep;13(11):1026-33. doi: 10.4161/cbt.20992. Epub 2012 Jul 24.

Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):186-93. doi: 10.1016/j.jsbmb.2012.05.004. Epub 2012 May 24.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

The organochlorine o,p’-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells.

Bratton MR, Frigo DE, Segar HC, Nephew KP, McLachlan JA, Wiese TE, Burow ME.

Environ Health Perspect. 2012 Sep;120(9):1291-6. doi: 10.1289/ehp.1104296. Epub 2012 May 18.

The microRNA expression associated with morphogenesis of breast cancer cells in three-dimensional organotypic culture.

Nguyen HT, Li C, Lin Z, Zhuang Y, Flemington EK, Burow ME, Lin Y, Shan B.

Oncol Rep. 2012 Jul;28(1):117-26. doi: 10.3892/or.2012.1764. Epub 2012 Apr 19.

Gαo potentiates estrogen receptor α activity via the ERK signaling pathway.

Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, Burow ME.

J Endocrinol. 2012 Jul;214(1):45-54. doi: 10.1530/JOE-12-0097. Epub 2012 May 4.

Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

Antoon JW, White MD, Burow ME, Beckman BS.

Oncol Rep. 2012 Jun;27(6):1779-86. doi: 10.3892/or.2012.1743. Epub 2012 Mar 27.

Environmental signaling and reproduction: a comparative biological and chemical perspective.

McLachlan JA, Tilghman SL, Burow ME, Bratton MR.

Mol Cell Endocrinol. 2012 May 6;354(1-2):60-2. doi: 10.1016/j.mce.2011.11.028. Epub 2011 Dec 8. Review.

MEK5/ERK5 pathway: the first fifteen years.

Drew BA, Burow ME, Beckman BS.

Biochim Biophys Acta. 2012 Jan;1825(1):37-48. doi: 10.1016/j.bbcan.2011.10.002. Epub 2011 Oct 13. Review.

The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.

Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM.

Oncol Rep. 2012 Jan;27(1):10-6. doi: 10.3892/or.2011.1488. Epub 2011 Oct 4.

Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells.

Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME.

Exp Cell Res. 2011 Nov 1;317(18):2573-81. doi: 10.1016/j.yexcr.2011.08.016. Epub 2011 Aug 30.

Pharmacological Inhibition of Sphingosine Kinase Isoforms Alters Estrogen Receptor Signaling in Human Breast Cancer.Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS.J Mol Endocrinol. 2011 Feb 14.

Targeting NF-ĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.

Antoon JW, White MD, Slaughter EM, Davis JL, Khalili HS, Elliott S, Smith CD, Burow ME, Beckman BS.

Cancer Biol Ther. 2011 Apr 1;11(7).

Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.

Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM.

Breast Cancer Res. 2010;12(6):R107.

Estrogenic and antiestrogenic activities of phytoalexins from red kidney bean (Phaseolus vulgaris L.).

Boué SM, Burow ME, Wiese TE, Shih BY, Elliott S, Carter-Wientjes CH, McLachlan JA, Bhatnagar D.

J Agric Food Chem. 2011 Jan 12;59(1):112-20.

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.

Cancer Res. 2011 Jan 15;71(2):603-13

Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME.

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.

Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP.

Oncogene. 2010 Nov 8

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE.

Carcinogenesis. 2010 Dec;31(12):2049-57.

Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS.

Endocrinology. 2010 Nov;151(11):5124-35

Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.

Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, Wang G.

J Med Chem. 2010 Aug 26;53(16):6153-63.

Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival.

Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA, Burow ME.

Int J Oncol. 2010 Sep;37(3):541-50.

Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression.

Rhodes LV, Burow ME.

ScientificWorldJournal. 2010 Jun 15;10:1084-7

Glyceollin I enantiomers distinctly regulate ER-mediated gene expression.

Payton-Stewart F, Khupse RS, Boué SM, Elliott S, Zimmermann MC, Skripnikova EV, Ashe H, Tilghman SL, Beckman BS, Cleveland TE, McLachlan JA, Bhatnagar D, Wiese TE, Erhardt P, Burow ME.

Steroids. 2010 Dec;75(12):870-8. Epub 2010 May 21.

Systems genetics analyses predict a transcription role for P2P-R: molecular confirmation that P2P-R is a transcriptional co-repressor.

Peidis P, Giannakouros T, Burow ME, Williams RW, Scott RE.

BMC Syst Biol. 2010 Feb 25;4:14.

Requirement of a novel splicing variant of human histone deacetylase 6 for TGF-beta1-mediated gene activation.

Zhuang Y, Nguyen HT, Lasky JA, Cao S, Li C, Hu J, Guo X, Burow ME, Shan B.

Biochem Biophys Res Commun. 2010 Feb 19;392(4):608-13.

Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events.

Struckhoff AP, Vitko JR, Rana MK, Davis CT, Foderingham KE, Liu CH, Vanhoy-Rhodes L, Elliott S, Zhu Y, Burow M, Worthylake RA.

J Cell Sci. 2010 Feb 1;123(Pt 3):401-12

Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy.

Zimmermann MC, Tilghman SL, Boué SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MH, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME.

J Pharmacol Exp Ther. 2010 Jan;332(1):35-45

Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.

Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M.

J Med Chem. 2009 Sep 24;52(18):5748-52.

Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence.

Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME.

Breast Cancer Res Treat. 2010 Jun;121(2):293-300

Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.

Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS.

Exp Biol Med (Maywood). 2009 Nov;234(11):1253-63.

Phytoalexin-enriched functional foods.

Boue SM, Cleveland TE, Carter-Wientjes C, Shih BY, Bhatnagar D, McLachlan JM, Burow ME.

J Agric Food Chem. 2009 Apr 8;57(7):2614-22.

Molecular effects of soy phytoalexin glyceollins in human prostate cancer cells LNCaP.

Payton-Stewart F, Schoene NW, Kim YS, Burow ME, Cleveland TE, Boue SM, Wang TT.

Mol Carcinog. 2009 Sep;48(9):862-71.

Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation.

Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA.

Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max).

Boué SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, Miraflor AP, Howell MH, Shih BY, Carter-Wientjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME.

Endocrinology. 2009 May;150(5):2446-53.

Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.

Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G.

Breast Cancer Res. 2008;10(6):R105.

Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.

Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo VA, Burow ME, Rowan BG.

Breast Cancer Res Treat. 2009 Nov;118(1):33-43.

Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase.

Bratton MR, Frigo DE, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, Burow ME.

Detecting ligands and dissecting nuclear receptor-signaling pathways using recombinant strains of the yeast Saccharomyces cerevisiae.

Fox JE, Burow ME, McLachlan JA, Miller CA 3rd.

Nat Protoc. 2008;3(4):637-45.

Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.

Wei S, Daniel BJ, Brumlik MJ, Burow ME, Zou W, Khan IA, Wadsworth S, Siekierka J, Curiel TJ.

Antimicrob Agents Chemother. 2007 Dec;51(12):4324-8.

Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.

Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME.

Int J Oncol. 2007 Oct;31(4):705-11.

Pesticides reduce symbiotic efficiency of nitrogen-fixing rhizobia and host plants.

Fox JE, Gulledge J, Engelhaupt E, Burow ME, McLachlan JA.

Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10282-7

Effects of soybean glyceollins and estradiol in postmenopausal female monkeys.

Wood CE, Clarkson TB, Appt SE, Franke AA, Boue SM, Burow ME, McCoy T, Cline JM.

Nutr Cancer. 2006;56(1):74-81.

Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies.

Lacey MR, Brumlik MJ, Yenni RE, Burow ME, Curiel TJ.

J Mol Evol. 2007 Jan;64(1):4-14.

Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis.

Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA, Cleveland TE, Burow ME.

Clin Cancer Res. 2006 Dec 1;12(23):7159-64

AKT regulation of estrogen receptor beta transcriptional activity in breast cancer.

Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME.

Cancer Res. 2006 Sep 1;66(17):8373-81.

p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1.

Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel TJ, Rowan BG, McLachlan JA, Burow ME.

Mol Endocrinol. 2006 May;20(5):971-83

Macrophage migration inhibitory factor: a central regulator of wound healing.

Hardman MJ, Waite A, Zeef L, Burow M, Nakayama T, Ashcroft GS.

Am J Pathol. 2005 Dec;167(6):1561-74.

Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins.

Kiefer TL, Lai L, Yuan L, Dong C, Burow ME, Hill SM.

J Pineal Res. 2005 May;38(4):231-9.

PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling.

Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS.

Int J Oncol. 2005 Mar;26(3):763-8.

Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway.

Frigo DE, Vigh KA, Struckhoff AP, Elliott S, Beckman BS, Burow ME, McLachlan JA.

Toxicol Lett. 2005 Feb 15;155(2):227-38.

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE.

J Cell Biol. 2004 Nov 8;167(3):469-78.

Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii.

Brumlik MJ, Wei S, Finstad K, Nesbit J, Hyman LE, Lacey M, Burow ME, Curiel TJ.

Int J Parasitol. 2004 Oct;34(11):1245-54.

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W.

Nat Med. 2004 Sep;10(9):942-9. Epub 2004 Aug 22.

Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators.

Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME.

Surgery. 2004 Aug;136(2):346-54.

Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.

Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME.

Int J Oncol. 2004 Jun;24(6):1473-80.

Phytoestrogen signaling and symbiotic gene activation are disrupted by endocrine-disrupting chemicals.

Fox JE, Starcevic M, Jones PE, Burow ME, McLachlan JA.

Environ Health Perspect. 2004 May;112(6):672-7.

Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.

Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS.

J Pharmacol Exp Ther. 2004 May;309(2):523-32. Epub 2004 Jan 23.

Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway.

Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA.

Carcinogenesis. 2004 Feb;25(2):249-61

Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system.

Simstein R, Burow M, Parker A, Weldon C, Beckman B.

Exp Biol Med (Maywood). 2003 Oct;228(9):995-1003. Review.

Symbiotic gene activation is interrupted by endocrine disrupting chemicals.

Fox JE, Burow ME, McLachlan JA.

ScientificWorldJournal. 2001 Nov 13;1:653-5. Review.

Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor.

Ashcroft GS, Mills SJ, Lei K, Gibbons L, Jeong MJ, Taniguchi M, Burow M, Horan MA, Wahl SM, Nakayama T.

J Clin Invest. 2003 May;111(9):1309-18.

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W.

Nat Med. 2003 May;9(5):562-7. Epub 2003 Apr 21.

Evaluation of the estrogenic effects of legume extracts containing phytoestrogens.

Boué SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA, Cleveland TE.

J Agric Food Chem. 2003 Apr 9;51(8):2193-9.

NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression.

Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS.

Exp Hematol. 2002 Dec;30(12):1419-27.

DDT and its metabolites alter gene expression in human uterine cell lines through estrogen receptor-independent mechanisms.

Frigo DE, Burow ME, Mitchell KA, Chiang TC, McLachlan JA.

Environ Health Perspect. 2002 Dec;110(12):1239-45.

Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.

Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME.

Surgery. 2002 Aug;132(2):293-301.

Flavonoid phytochemicals regulate activator protein-1 signal transduction pathways in endometrial and kidney stable cell lines.

Frigo DE, Duong BN, Melnik LI, Schief LS, Collins-Burow BM, Pace DK, McLachlan JA, Burow ME.

J Nutr. 2002 Jul;132(7):1848-53.

Silica-induced apoptosis in murine macrophage: involvement of tumor necrosis factor-alpha and nuclear factor-kappaB activation.

Gozal E, Ortiz LA, Zou X, Burow ME, Lasky JA, Friedman M.

Am J Respir Cell Mol Biol. 2002 Jul;27(1):91-8.

Promoter CpG methylation of Hox-a10 and Hox-a11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure.

Li S, Ma L, Chiang T, Burow M, Newbold RR, Negishi M, Barrett JC, McLachlan JA.

Mol Carcinog. 2001 Dec;32(4):213-9.

Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.

Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS.

J Steroid Biochem Mol Biol. 2001 Nov;78(5):409-18.

Endocrine disruption in sexual differentiation and puberty. What do pseudohermaphroditic polar bears have to do with the practice of pediatrics?

Gulledge CC, Burow ME, McLachlan JA.

Pediatr Clin North Am. 2001 Oct;48(5):1223-40, x. Review.

Nitrogen fixation. Endocrine disrupters and flavonoid signalling.

Fox JE, Starcevic M, Kow KY, Burow ME, McLachlan JA.

Nature. 2001 Sep 13;413(6852):128-9.

Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms.

Collins-Burow BM, Burow ME, Duong BN, McLachlan JA.

Nutr Cancer. 2000;38(2):229-44.

NF-kappa B-mediated chemoresistance in breast cancer cells.

Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS.

Surgery. 2001 Aug;130(2):143-50.

From malformations to molecular mechanisms in the male: three decades of research on endocrine disrupters.

McLachlan JA, Newbold RR, Burow ME, Li SF.

APMIS. 2001 Apr;109(4):263-72. Review.

Effects of estrogen on leptin gene promoter activation in MCF-7 breast cancer and JEG-3 choriocarcinoma cells: selective regulation via estrogen receptors alpha and beta.

O’Neil JS, Burow ME, Green AE, McLachlan JA, Henson MC.

Mol Cell Endocrinol. 2001 May 15;176(1-2):67-75.

Gene imprinting in developmental toxicology: a possible interface between physiology and pathology.

McLachlan JA, Burow M, Chiang TC, Li SF.

Toxicol Lett. 2001 Mar 31;120(1-3):161-4. Review.

Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta.

Burow ME, Boue SM, Collins-Burow BM, Melnik LI, Duong BN, Carter-Wientjes CH, Li S, Wiese TE, Cleveland TE, McLachlan JA.

J Clin Endocrinol Metab. 2001 Apr;86(4):1750-8.

Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor.

Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, Tou J.

J Biol Chem. 2000 Sep 8;275(36):27694-702.

Differences in protein kinase C and estrogen receptor alpha, beta expression and signaling correlate with apoptotic sensitivity of MCF-7 breast cancer cell variants.

Burow ME, Weldon CB, Chiang TC, Tang Y, Collins-Burow BM, Rolfe K, Li S, McLachlan JA, Beckman BS.

Int J Oncol. 2000 Jun;16(6):1179-87.

PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis.

Burow ME, Weldon CB, Melnik LI, Duong BN, Collins-Burow BM, Beckman BS, McLachlan JA.

Biochem Biophys Res Commun. 2000 May 10;271(2):342-5.

Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions.

Burow ME, Weldon CB, Collins-Burow BM, Ramsey N, McKee A, Klippel A, McLachlan JA, Clejan S, Beckman BS.

J Biol Chem. 2000 Mar 31;275(13):9628-35.

Effects of cadmium cell viability, trophoblastic development, and expression of low density lipoprotein receptor transcripts in cultured human placental cells.

Jolibois LS Jr, Burow ME, Swan KF, George WJ, Anderson MB, Henson MC.

Reprod Toxicol. 1999 Nov-Dec;13(6):473-80.

Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells.

Burow ME, Tang Y, Collins-Burow BM, Krajewski S, Reed JC, McLachlan JA, Beckman BS.

Carcinogenesis. 1999 Nov;20(11):2057-61

Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants.

Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS.

Cancer Res. 1998 Nov 1;58(21):4940-6.